Latest Cyclopyrrolones Stories
ANN ARBOR, Mich., Jan.
Need the help of a pill to catch some zzzâ€™s? According to a new study youâ€™re not alone; the use of prescription sleep aids nearly tripled among young adults between 1998 and 2006.
US-based pharmaceutical company Sepracor has announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion recommending to grant a marketing authorization for Lunivia brand eszopiclone in the EU for the treatment of insomnia.
Sepracor Inc. (Nasdaq: SEPR) today announced that the EMEA's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending to grant a marketing authorization for LUNIVIA(R) brand eszopiclone in the European Union (EU) for the treatment of insomnia.
LEXINGTON, Mass., Sept. 26 /PRNewswire/ -- Indevus Pharmaceuticals, Inc. today announced that it has signed a development, license and commercialization agreement with Teva Pharmaceutical Industries Ltd. for the exclusive, worldwide rights to pagoclone.
-- Elderly patients taking LUNESTA 2 mg showed significant improvements in measures of daytime function compared to placebo over a 12-week treatment period -- Elderly patients administered LUNESTA 2 mg showed no evidence of rebound insomnia and withdrawal symptoms were comparable to the placebo group upon discontinuation Sepracor Inc.
Sepracor Inc. (Nasdaq: SEPR) today announced the presentation of LUNESTA(R) brand eszopiclone Phase IV study data at the 21st European College of Neuropsychopharmacology (ECNP) Congress in Barcelona.
SAN DIEGO, Aug. 18 /PRNewswire/ -- The next time you consider popping a pill when you have trouble nodding off, it might be worth counting sheep instead. A senior psychiatrist at the Scripps Clinic Sleep Center in San Diego, Calif.
A GIFTED disabled boy died after doctors mistakenly gave him a "cocktail of drugs" forbidden by medical textbooks, an inquest heard.
Sepracor Inc. (Nasdaq: SEPR) today announced the presentation of Phase III combined clinical results for eslicarbazepine acetate (SEP-0002093 / BIA 2-093) in the treatment of epilepsy at the Ninth Eilat Conference on New Anti-Epileptic Drugs in Spain.
- totally perplexed and mixed up.